Literature DB >> 31644387

Stuck in the window with you: HIV exposure prophylaxis in the highest risk people who inject drugs.

Jessica L Taylor1, Alexander Y Walley1, Angela R Bazzi2.   

Abstract

The opioid and polysubstance epidemics could drive a surge in new HIV infections among people who inject drugs (PWID). Longstanding strategies to reduce HIV incidence, including syringe service programs, condom distribution, medications for opioid use disorder, and low-barrier HIV testing and treatment have not been adequate to eliminate transmission in this population. Although HIV pre-exposure prophylaxis (PrEP) is an evidence-based intervention that reduces HIV incidence among PWID, uptake in PWID has lagged due to limited PrEP knowledge, discrepancies between perceived and actual HIV risk, stigma, and structural barriers to adherence including homelessness and incarceration. In our efforts to deploy PrEP to PWID in our low-barrier substance use disorder bridge clinic, we have encountered another barrier: the HIV testing window period. We discuss challenges in delivering HIV exposure prophylaxis to the highest risk PWID, our current approach, and the need for more data to guide best practices.

Entities:  

Keywords:  HIV prevention; PEP; PrEP; injection drug use; opioid use disorder; people who inject drugs

Year:  2019        PMID: 31644387     DOI: 10.1080/08897077.2019.1675118

Source DB:  PubMed          Journal:  Subst Abus        ISSN: 0889-7077            Impact factor:   3.716


  8 in total

1.  Sexually Transmitted and Blood-borne Infections Among Patients Presenting to a Low-barrier Substance Use Disorder Medication Clinic.

Authors:  Leah Harvey; Jessica L Taylor; Sabrina A Assoumou; Jessica Kehoe; Elissa M Schechter-Perkins; Edward Bernstein; Alexander Y Walley
Journal:  J Addict Med       Date:  2021 Nov-Dec 01       Impact factor: 3.702

2.  Long-Acting Injectable Human Immunodeficiency Virus Pre-Exposure Prophylaxis Preferred Over Other Modalities Among People Who Inject Drugs: Findings from a Qualitative Study in California.

Authors:  Angela R Bazzi; Chad J Valasek; Samantha A Streuli; Carlos F Vera; Alicia Harvey-Vera; Morgan M Philbin; Katie B Biello; Alexis M Roth; Steffanie A Strathdee; Heather A Pines
Journal:  AIDS Patient Care STDS       Date:  2022-06-21       Impact factor: 5.944

3.  Patient and Provider Perspectives on a Novel, Low-Threshold HIV PrEP Program for People Who Inject Drugs Experiencing Homelessness.

Authors:  Angela R Bazzi; Leah C Shaw; Katie B Biello; Seamus Vahey; Jennifer K Brody
Journal:  J Gen Intern Med       Date:  2022-05-25       Impact factor: 6.473

Review 4.  Infective Endocarditis in Persons Who Use Drugs: Epidemiology, Current Management, and Emerging Treatments.

Authors:  Asher Schranz; Joshua A Barocas
Journal:  Infect Dis Clin North Am       Date:  2020-09       Impact factor: 5.982

Review 5.  Harm Reduction Services to Prevent and Treat Infectious Diseases in People Who Use Drugs.

Authors:  Kinna Thakarar; Katherine Nenninger; Wollelaw Agmas
Journal:  Infect Dis Clin North Am       Date:  2020-09       Impact factor: 5.982

6.  A collision of crises: Addressing an HIV outbreak among people who inject drugs in the midst of COVID-19.

Authors:  Jessica L Taylor; Glorimar Ruiz-Mercado; Heather Sperring; Angela R Bazzi
Journal:  J Subst Abuse Treat       Date:  2021-01-07

Review 7.  The Past, Present, and Future of PrEP implementation Among People Who Use Drugs.

Authors:  Katie B Biello; Matthew J Mimiaga; Pablo K Valente; Nimish Saxena; Angela R Bazzi
Journal:  Curr HIV/AIDS Rep       Date:  2021-04-27       Impact factor: 5.495

8.  Missed opportunities to prevent HIV infections among pre-exposure prophylaxis users: a population-based mixed methods study, San Francisco, United States.

Authors:  Matthew A Spinelli; Nicole Laborde; Patrick Kinley; Ryan Whitacre; Hyman M Scott; Nicole Walker; Albert Y Liu; Monica Gandhi; Susan P Buchbinder
Journal:  J Int AIDS Soc       Date:  2020-04       Impact factor: 5.396

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.